Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1910 1
1948 1
1950 1
1951 1
1953 2
1954 1
1958 2
1960 1
1961 2
1962 3
1963 1
1964 1
1965 1
1969 1
1970 1
1975 1
1976 1
1977 1
1978 1
1979 1
1980 1
1981 1
1983 1
1984 2
1985 2
1989 2
1990 3
1991 4
1992 1
1993 2
1994 3
1995 3
1996 1
1997 3
1998 4
1999 1
2000 1
2002 3
2003 1
2004 3
2005 1
2006 3
2007 4
2008 9
2009 6
2010 3
2011 5
2012 9
2013 8
2014 8
2015 11
2016 10
2017 14
2018 13
2019 12
2020 20
2021 20
2022 13
2023 12
2024 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

236 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, Hong HC, Katoh N, Valenzuela F, DiBonaventura M, Bratt TA, Zhang F, Clibborn C, Rojo R, Valdez H, Kerkmann U. Reich K, et al. Among authors: valenzuela f. Lancet. 2022 Jul 23;400(10348):273-282. doi: 10.1016/S0140-6736(22)01199-0. Lancet. 2022. PMID: 35871814 Clinical Trial.
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.
Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, Gubelin W, Simpson EL, Valenzuela F, Criado PR, Lebwohl MG, Feeney C, Khan T, Biswas P, DiBonaventura M, Valdez H, Cameron MC, Rojo R. Blauvelt A, et al. Among authors: valenzuela f. J Am Acad Dermatol. 2022 Jan;86(1):104-112. doi: 10.1016/j.jaad.2021.05.075. Epub 2021 Aug 17. J Am Acad Dermatol. 2022. PMID: 34416294 Free article. Clinical Trial.
Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis.
Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, Rademaker M, Fomina D, Gutermuth J, Ahn J, Valenzuela F, Ameen M, Steinhoff M, Kirchhof MG, Lio P, Wollenberg A. Silverberg JI, et al. Among authors: valenzuela f. J Eur Acad Dermatol Venereol. 2024 Nov;38(11):2139-2148. doi: 10.1111/jdv.20229. Epub 2024 Jul 11. J Eur Acad Dermatol Venereol. 2024. PMID: 38989857
Psoriasis in Latin America.
Chouela E, Amaya M, Londoño A, Romiti R, Valenzuela F, Duarte AA, Perez Alfonzo R, Borlenghi C. Chouela E, et al. Among authors: valenzuela f. Dermatol Online J. 2016 Sep 15;22(9):13030/qt4wn3m8xt. Dermatol Online J. 2016. PMID: 28329605 Review.
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Griffiths CE, et al. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. Lancet. 2015. PMID: 26072109 Clinical Trial.
The role of excimer light in dermatology: a review.
Hartmann Schatloff D, Retamal Altbir C, Valenzuela F. Hartmann Schatloff D, et al. Among authors: valenzuela f. An Bras Dermatol. 2024 Nov-Dec;99(6):887-894. doi: 10.1016/j.abd.2023.12.007. Epub 2024 Aug 5. An Bras Dermatol. 2024. PMID: 39107199 Free PMC article. Review.
Circadian rhythms in the fetus.
Serón-Ferré M, Mendez N, Abarzua-Catalan L, Vilches N, Valenzuela FJ, Reynolds HE, Llanos AJ, Rojas A, Valenzuela GJ, Torres-Farfan C. Serón-Ferré M, et al. Among authors: valenzuela fj. Mol Cell Endocrinol. 2012 Feb 5;349(1):68-75. doi: 10.1016/j.mce.2011.07.039. Epub 2011 Aug 5. Mol Cell Endocrinol. 2012. PMID: 21840372 Review.
ThyroidPrint®: clinical utility for indeterminate thyroid cytology.
Olmos R, Domínguez JM, Vargas-Salas S, Mosso L, Fardella CE, González G, Baudrand R, Guarda F, Valenzuela F, Arteaga E, Forenzano P, Nilo F, Lustig N, Martínez A, López JM, Cruz F, Loyola S, Leon A, Droppelmann N, Montero P, Domínguez F, Camus M, Solar A, Zoroquiain P, Roa JC, Muñoz E, Bruce E, Gajardo R, Miranda G, Riquelme F, Mena N, González HE. Olmos R, et al. Among authors: valenzuela f. Endocr Relat Cancer. 2023 Oct 6;30(11):e220409. doi: 10.1530/ERC-22-0409. Print 2023 Nov 1. Endocr Relat Cancer. 2023. PMID: 37671897 Free PMC article.
Pathogenesis of preeclampsia: the genetic component.
Valenzuela FJ, Pérez-Sepúlveda A, Torres MJ, Correa P, Repetto GM, Illanes SE. Valenzuela FJ, et al. J Pregnancy. 2012;2012:632732. doi: 10.1155/2012/632732. Epub 2011 Dec 1. J Pregnancy. 2012. PMID: 22175024 Free PMC article. Review.
236 results